drugset
drugset / Trial / NCT03285802

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

NCT03285802 ↗

Phase 2/3 Completed 1 enrolled Greater Baltimore Medical Center
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label treatment program following basic prescribing information for patients with recurrent UPSC (Uterine Papillary Serous Carcinoma) to provide access to everolimus and limited treatment alternatives.

Timeline

Start
2017-09-07
Primary completion
2019-02-12
Completion
2019-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 10 mg —
Subject Letrozole Other / unclassified 2.5 mg —

Indications

uterine cancer